Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH

Cancer-specific mutations can lead to peptides of unique sequence presented on MHC class I to CD8 T cells. These neoantigens can be potent tumour-rejection antigens, appear to be the driving force behind responsiveness to anti-CTLA-4 and anti-PD1/L1-based therapies and have been used to develop pers...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open Biol
Hauptverfasser: Crowley, Stephanie J., Bruck, Patrick T., Bhuiyan, Md Aladdin, Mitchell-Gears, Amelia, Walsh, Michael J., Zhangxu, Kevin, Ali, Lestat R., Jeong, Hee-Jin, Ingram, Jessica R., Knipe, David M., Ploegh, Hidde L., Dougan, Michael, Dougan, Stephanie K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: The Royal Society 2020
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058936/
https://ncbi.nlm.nih.gov/pubmed/32019478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1098/rsob.190235
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge